期刊文献+

GST-gAD在大肠杆菌中的优化表达及其生物活性测定 被引量:1

Optimizing Expression in E.coli and Bioactivity Assay of Recombinant GST-gAD
下载PDF
导出
摘要 目的探讨可溶性重组脂联素球状结构域融合蛋白(GST-gAD)在大肠杆菌中的优化表达及其抑制人乳腺癌细胞MDA-MB-231增殖的生物学活性。方法用含有GST-gAD基因的原核表达载体pGEX-KG-gAD转化E.coli J M109,同理空载质粒pGEX-KG作为内对照同时转化E.coli J M109;将影响融合蛋白表达的4个因素,温度、IPTG浓度、细菌密度OD600和诱导时间进行正交设计,确定其优化表达条件,用亲和层析法纯化GST-gAD;用MTT法检测GST-gAD对MDA-MB-231增殖的影响。结果GST-gAD最佳表达条件为温度32℃,IPTG的浓度1.0mmol/L,诱导前细菌密度OD6001.0,诱导表达时间1.5h。GST-gAD浓度高于0.5μmol/L时对MDA-MB-231细胞的生长具有明显的抑制作用。结论通过正交设计确定了可溶性GST-gAD融合蛋白在大肠杆菌中表达的优化条件并且当重组融合蛋白在大于0.5μmol/L时对MDA-MB-231细胞的生长具有明显的抑制作用。 Objective To explore the best expressing condition of the recombinan human globular domain of human adiponection(gAD) and study its bioactivity. Methods The plasmid pGEX- KG-gAD and the empty plasmid pGEX-KG, as control, were transformated into E. eoli host JM109. The best expressing condition of GST-gAD was explored through orthogonal design which took growth temperature, IPTG concentration, culture density,incubation time as indices. The expressed products(GST-gAD) proteins were purified from supernatant bacterial lysates by affinity chromatography using reduced glutathione resin. The effect of GST-gAD on proliferation of MDA-MB-231 cells were measured by MTT essay. Results The expression level was the highest in the conditions of OD600 value 1.0,1.0 mmol/L IPTG,under 32 ℃ and 1.5 hours of induction time. The growth ability of MDA-MB-231 cells were obviously Inhibited when concentration of GST-gAD was higher than 0.5/,mol/L. Conclusion The best expressing condition of the recombinant GST-gAD in E. coli was determined through orthogonal design and GST-gAD show natural biological activities.
出处 《江西医学院学报》 CAS 2008年第3期12-15,共4页 Acta Academiae Medicinae Jiangxi
关键词 脂联素 球状结构域 重组蛋白表达 乳腺癌细胞 adiponectin globular domain expression of recombinant protein breast carcinoma cell line
  • 相关文献

参考文献9

  • 1Arita Y, Kihara S, Ouchi N. Paradoxiael Decrease of an Adipose-specific Protein, Adiponectin,in Obesity[J]. Biochem Bioplays Res Commun, 1999,257(1) : 79-83.
  • 2Chandran M, Phillips S A, Ciaraldi T, et al. Adiponectin: more than Just Another Fat Cell Hormone[J], Diab Care, 2003,26 : 2442-2450.
  • 3Trujillo M E,Scherer P E. Adiponectin-journey from an Adipocyte Secretor Protein to Biomarker of the Metabolic Syndrome[J]. J Intern Med,2005,257:167-175.
  • 4Housa D, Housova J, Vernerova Z, et al. Adipocytokines and Cancer[J]. Physiol Res, 2006,55 (3) : 233-244.
  • 5Petridou E, Mantzoros C, Dessypris N, et al. Plasma Adiponectin Concentrations in Relation to Endometrial Cancer: a Case-control Study in Greece[J]. J Clin Endocrino Meta, 2003,88 : 993-997.
  • 6Mantzoros C,Petridou E, Dessypris N, et al. Adiponectin and Breast Cancer Risk[J]. J Clin Endocrinol Meta, 2004,89 : 1102- 1107.
  • 7Wei E K,Giovannucci E, Fuchs C S, et al. Plasma Adiponectin Levels and the Risk of Colorectal Cancer in Men[J]. J Natl Cancer Inst,2005,97(22) : 1688-1694.
  • 8lshlkawa M, Kitayama J, Kazama S, et al. Plasma Adiponectin and Gastric Cancer[J]. Clin Cancer Res, 2005,11: 466-472.
  • 9Goktas S,Yilmaz M I,Caglar K,et al. Rostate Cancer and Adiponectin[J]. Urology,2005,65 : 1168-1172.

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部